These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532 [TBL] [Abstract][Full Text] [Related]
4. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW; JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836 [TBL] [Abstract][Full Text] [Related]
5. Serial Baseline, 12-, 24-, and 60-Month Optical Coherence Tomography Evaluation of ST Segment Elevation Myocardial Infarction Patients Treated with Absorb Bioresorbable Vascular Scaffold. Koltowski L; Tomaniak M; Ochijewicz D; Zieliński K; Proniewska K; Malinowski KP; Zaleska M; Maksym J; Roleder T; Partyka L; Kochman W; Filipiak KJ; Opolski G; Kochman J Am J Cardiol; 2021 Sep; 155():23-31. PubMed ID: 34315572 [TBL] [Abstract][Full Text] [Related]
6. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Brugaletta S; Radu MD; Garcia-Garcia HM; Heo JH; Farooq V; Girasis C; van Geuns RJ; Thuesen L; McClean D; Chevalier B; Windecker S; Koolen J; Rapoza R; Miquel-Hebert K; Ormiston J; Serruys PW Atherosclerosis; 2012 Mar; 221(1):106-12. PubMed ID: 22209268 [TBL] [Abstract][Full Text] [Related]
7. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging. Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768 [TBL] [Abstract][Full Text] [Related]
8. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. Bourantas CV; Serruys PW; Nakatani S; Zhang YJ; Farooq V; Diletti R; Ligthart J; Sheehy A; van Geuns RJ; McClean D; Chevalier B; Windecker S; Koolen J; Ormiston J; Whitbourn R; Rapoza R; Veldhof S; Onuma Y; Garcia-Garcia HM EuroIntervention; 2015 Nov; 11(7):746-56. PubMed ID: 25308301 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry. Yamaji K; Ueki Y; Souteyrand G; Daemen J; Wiebe J; Nef H; Adriaenssens T; Loh JP; Lattuca B; Wykrzykowska JJ; Gomez-Lara J; Timmers L; Motreff P; Hoppmann P; Abdel-Wahab M; Byrne RA; Meincke F; Boeder N; Honton B; O'Sullivan CJ; Ielasi A; Delarche N; Christ G; Lee JKT; Lee M; Amabile N; Karagiannis A; Windecker S; Räber L J Am Coll Cardiol; 2017 Nov; 70(19):2330-2344. PubMed ID: 29096803 [TBL] [Abstract][Full Text] [Related]
10. Re-endothelialisation after Synergy stent and Absorb bioresorbable vascular scaffold implantation in acute myocardial infarction: COVER-AMI study. Lhermusier T; Ohayon P; Boudou N; Bouisset F; Campelo-Parada F; Roncalli J; Elbaz M; Carrié D Trials; 2019 Apr; 20(1):210. PubMed ID: 30975219 [TBL] [Abstract][Full Text] [Related]
12. Neoatherosclerosis development following bioresorbable vascular scaffold implantation in diabetic and non-diabetic swine. van Ditzhuijzen NS; Kurata M; van den Heuvel M; Sorop O; van Duin RWB; Krabbendam-Peters I; Ligthart J; Witberg K; Murawska M; Bouma B; Villiger M; Garcia-Garcia HM; Serruys PW; Zijlstra F; van Soest G; Duncker DJ; Regar E; van Beusekom HMM PLoS One; 2017; 12(9):e0183419. PubMed ID: 28898243 [TBL] [Abstract][Full Text] [Related]
13. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961 [TBL] [Abstract][Full Text] [Related]
15. Is bioresorbable vascular scaffold acute recoil affected by baseline renal function and scaffold selection? Gunes HM; Yılmaz FK; Gokdeniz T; Demir GG; Guler E; Guler GB; Karaca O; Cakal B; İbişoğlu E; Boztosun B Int J Cardiol; 2016 Dec; 224():388-393. PubMed ID: 27681252 [TBL] [Abstract][Full Text] [Related]
16. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897 [TBL] [Abstract][Full Text] [Related]